225 related articles for article (PubMed ID: 30768358)
1. RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.
Gong S; Chen Y; Meng F; Zhang Y; Wu H; Li C; Zhang G
FASEB J; 2019 Apr; 33(4):5350-5365. PubMed ID: 30768358
[TBL] [Abstract][Full Text] [Related]
2. RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.
Wu N; Ren D; Li S; Ma W; Hu S; Jin Y; Xiao S
BMC Cancer; 2018 Jan; 18(1):67. PubMed ID: 29321004
[TBL] [Abstract][Full Text] [Related]
3. RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma.
Chen Q; Jiang P; Jia B; Liu Y; Zhang Z
Hum Cell; 2020 Jul; 33(3):709-720. PubMed ID: 32239438
[TBL] [Abstract][Full Text] [Related]
4. RCC2 Interacts with Small GTPase RalA and Regulates Cell Proliferation and Motility in Gastric Cancer.
Wang P; Zhang W; Wang L; Liang W; Cai A; Gao Y; Chen L
Onco Targets Ther; 2020; 13():3093-3103. PubMed ID: 32341655
[TBL] [Abstract][Full Text] [Related]
5. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
[TBL] [Abstract][Full Text] [Related]
6. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.
Zhao J; Tan W; Zhang L; Liu J; Shangguan M; Chen J; Zhao B; Peng Y; Cui M; Zhao S
Biochem Pharmacol; 2021 Aug; 190():114536. PubMed ID: 33794187
[TBL] [Abstract][Full Text] [Related]
7. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F
Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985
[TBL] [Abstract][Full Text] [Related]
9. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
10. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer.
Yang X; Zheng F; Xing H; Gao Q; Wei W; Lu Y; Wang S; Zhou J; Hu W; Ma D
J Cancer Res Clin Oncol; 2004 Jul; 130(7):423-8. PubMed ID: 15156398
[TBL] [Abstract][Full Text] [Related]
11. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells.
Zhao WJ; Deng BY; Wang XM; Miao Y; Wang JN
Asian Pac J Cancer Prev; 2015; 16(6):2453-8. PubMed ID: 25824780
[TBL] [Abstract][Full Text] [Related]
12. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
Zhang TM
Chemotherapy; 2019; 64(3):119-128. PubMed ID: 31661694
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.
Zou W; Ma X; Yang H; Hua W; Chen B; Cai G
Exp Biol Med (Maywood); 2017 Mar; 242(5):497-504. PubMed ID: 28056551
[TBL] [Abstract][Full Text] [Related]
14. RCC2 promotes proliferation and radio-resistance in glioblastoma via activating transcription of DNMT1.
Yu H; Zhang S; Ibrahim AN; Wang J; Deng Z; Wang M
Biochem Biophys Res Commun; 2019 Aug; 516(3):999-1006. PubMed ID: 31277942
[TBL] [Abstract][Full Text] [Related]
15. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells.
Liu L; Fan J; Ai G; Liu J; Luo N; Li C; Cheng Z
Biol Res; 2019 Jul; 52(1):37. PubMed ID: 31319879
[TBL] [Abstract][Full Text] [Related]
16. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
17. RCC2 promotes prostate cancer cell proliferation and migration through Hh/GLI1 signaling pathway and cancer stem-like cells.
Wang S; Lei Z; Liu W; Xiong J; Shi Y; Yang L; Gao Q; Le K; Zhang B
Biol Direct; 2023 Nov; 18(1):80. PubMed ID: 38008751
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
19. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
20. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
